News - trastuzumab emtansine

Filter

Current filters:

trastuzumab emtansine

Popular Filters

Growing patient population to drive Mexican breast cancer market

20-02-2013

An expanding patient population will largely contribute to the growth of the market for treating breast…

AfinitorEisaiHalavenKadcylaMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheSouth Americatrastuzumab emtansine

Roche affiliate Chugai files for T-DM1 approval in Japan; gains rights to Afraxis compound

30-01-2013

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority owned by Swiss major Roche (ROG:…

AfraxisAsia-PacificChugai PharmaceuticalGenentechGlobalLicensingOncologyPharmaceuticalProductionRegulationRocheT-DM1trastuzumab emtansine

Genentech's T-DM1 significantly improved survival for metastatic breast cancer patients

29-08-2012

Swiss drug major Roche (ROG: SIX) US subsidiary Genentech has announced updated results from the Phase…

BiotechnologyGenentechOncologyPharmaceuticalRegulationResearchRocheT-DM1trastuzumab emtansine

ASCO 2012: "Show me the overall survival data," say analysts

07-06-2012

The annual American Society of Clinical Oncology (ASCO) meeting, held this year in Chicago from June…

GenentechJohnson & JohnsonOncologyPharmaceuticalResearchRochetrastuzumab emtansineZytiga

Flood of new cancer drug data presented at ASCO; nearly 1,000 being tested

04-06-2012

The annual prestigious American Society of Clinical Oncology (ASCO) meeting taking place in Chicago,…

afatinibBiotechnologyBoehringer IngelheimGenentechJanssenJohnson & JohnsonOncologyPharmaceuticalResearchRochetrastuzumab emtansineZytiga

Back to top